LAVAL, QC, May 19, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc. Dr. Roberts will serve as chair of the Science and Technology Committee.
Detailed results of the vote follow:
Name For Withheld Broker Non-
Votes
Thomas J. Appio 196,814,621 2,743,810 79,859,605
Christian A. Garcia 196,711,908 2,846,523 79,859,605
Michael Goettler 196,757,828 2,800,603 79,859,605
Sarah B. Kavanagh 188,459,870 11,098,561 79,859,605
Frank D. Lee 183,885,617 15,672,814 79,859,605
Sandra Leung 195,931,772 3,626,659 79,859,605
John A. Paulson 196,214,806 3,343,625 79,859,605
Robert N. Power 186,236,066 13,322,365 79,859,605
Eiry W. Roberts, M.D. 196,972,752 2,585,679 79,859,605
Amy B. Wechsler, M.D. 195,813,955 3,744,476 79,859,605
Shareholders also approved, on a non-binding advisory vote, the compensation of the Company's named executive officers, appointment of PricewaterhouseCoopers LLP to serve as the Company's auditor until the close of the Company's 2027 Annual Meeting of Shareholders, and the authorization for the board of directors to fix the auditor's remuneration.
The final vote tabulation on all matters voted on at the Annual Meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR+ profile and on the Company's website at www.bauschhealth.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit?www.bauschhealth.com?and connect with us on?LinkedIn.
Investor Contact: Media Contact:
Garen Sarafin
Katie Savastano
ir@bauschhealth.
com corporate.communications@bauschhealth.com
(877) 281-6642 (toll free)
(908) 569-3692
BHC-AGM
View original content to download multimedia:https://www.prnewswire.com/news-releases/bausch-health-announces-2026-annual-meeting-of-shareholder-results-302776740.html
SOURCE Bausch Health Companies Inc.
